DK1915620T3 - Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer - Google Patents

Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer

Info

Publication number
DK1915620T3
DK1915620T3 DK06795161.6T DK06795161T DK1915620T3 DK 1915620 T3 DK1915620 T3 DK 1915620T3 DK 06795161 T DK06795161 T DK 06795161T DK 1915620 T3 DK1915620 T3 DK 1915620T3
Authority
DK
Denmark
Prior art keywords
autoantibodies
vascular diseases
1alpha
contraception
diagnosis
Prior art date
Application number
DK06795161.6T
Other languages
English (en)
Inventor
John Simard
Klaus Bendtzen
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Application granted granted Critical
Publication of DK1915620T3 publication Critical patent/DK1915620T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK06795161.6T 2005-08-02 2006-07-26 Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer DK1915620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70445005P 2005-08-02 2005-08-02
PCT/IB2006/002038 WO2007015128A1 (en) 2005-08-02 2006-07-26 DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES

Publications (1)

Publication Number Publication Date
DK1915620T3 true DK1915620T3 (da) 2010-10-04

Family

ID=37442093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06795161.6T DK1915620T3 (da) 2005-08-02 2006-07-26 Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer

Country Status (11)

Country Link
US (2) US8187817B2 (da)
EP (2) EP1915620B1 (da)
JP (2) JP5645361B2 (da)
CN (2) CN101253409A (da)
AT (1) ATE470151T1 (da)
AU (1) AU2006274698B2 (da)
CA (1) CA2617637C (da)
DE (1) DE602006014691D1 (da)
DK (1) DK1915620T3 (da)
ES (1) ES2346691T3 (da)
WO (1) WO2007015128A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2346691T3 (es) * 2005-08-02 2010-10-19 Xbiotech, Inc Diagnostico, tratamiento y prevencion de trastornos vasculares usando autoanticuerpos il-1alfa.
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CA2652274A1 (en) * 2006-05-15 2007-11-22 Xbiotech Inc. Il-1.alpha. immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) * 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
ES2576681T3 (es) * 2008-05-30 2016-07-08 Xbiotech, Inc Anticuerpos IL-1 alfa
US8242074B2 (en) 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
US20130231257A1 (en) 2010-05-12 2013-09-05 The University Of Birmingham Biomarker
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
EP3443985B1 (en) 2010-08-23 2020-12-16 XBiotech, Inc Treatment for neoplastic diseases
WO2012067165A1 (ja) * 2010-11-17 2012-05-24 国立大学法人愛媛大学 自己免疫疾患に関与するタンパク質の解析方法及び該疾患の検査方法
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2013043973A2 (en) 2011-09-23 2013-03-28 Xbiotech, Inc. Cachexia treatment
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
SG11202008718UA (en) * 2018-03-09 2020-10-29 Brigham & Womens Hospital Inc Combination therapy for cardiovascular diseases
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2140469T3 (es) 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2002033408A1 (en) * 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting an inflammatory indicator in a body fluid sample
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
DK2213685T3 (da) 2002-09-06 2014-03-03 Medarex Llc Terapeutisk anti-IL-1R1-monoklonalt antistof
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
DK1819359T3 (da) 2004-12-09 2015-04-20 Janssen Biotech Inc Anti-integrin-immunokonjugater, fremgangsmåder til deres fremstilling og deres anvendelse
ES2346691T3 (es) * 2005-08-02 2010-10-19 Xbiotech, Inc Diagnostico, tratamiento y prevencion de trastornos vasculares usando autoanticuerpos il-1alfa.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
CA2652274A1 (en) 2006-05-15 2007-11-22 Xbiotech Inc. Il-1.alpha. immunization induces autoantibodies protective against atherosclerosis
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
PL2446904T3 (pl) 2006-05-30 2015-10-30 Genentech Inc Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
CN102056485A (zh) 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
ES2576681T3 (es) 2008-05-30 2016-07-08 Xbiotech, Inc Anticuerpos IL-1 alfa
US8242074B2 (en) 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
CA2749966A1 (en) 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins

Also Published As

Publication number Publication date
JP2013127469A (ja) 2013-06-27
DE602006014691D1 (de) 2010-07-15
CA2617637C (en) 2017-07-18
AU2006274698A2 (en) 2008-03-06
AU2006274698B2 (en) 2011-06-09
ATE470151T1 (de) 2010-06-15
CN101253409A (zh) 2008-08-27
JP5645361B2 (ja) 2014-12-24
US8865175B2 (en) 2014-10-21
JP2009503529A (ja) 2009-01-29
CA2617637A1 (en) 2007-02-08
JP5717256B2 (ja) 2015-05-13
EP1915620A1 (en) 2008-04-30
WO2007015128A1 (en) 2007-02-08
US8187817B2 (en) 2012-05-29
AU2006274698A1 (en) 2007-02-08
EP1915620B1 (en) 2010-06-02
ES2346691T3 (es) 2010-10-19
EP2216653A1 (en) 2010-08-11
CN109187944A (zh) 2019-01-11
US20120231012A1 (en) 2012-09-13
US20090123415A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
BRPI0416628A (pt) uso de compostos orgánicos
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200870325A1 (ru) Лекарственные формы для введения комбинаций лекарственных средств
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
NO20073816L (no) Kombinasjonsterapi for behandling av diabetes og tilstander relatert dertil og for behandling av tilstanden som er bedret ved a oke blod GLP-1 nivaet
ME02414B (me) Tretman kronove bolesti lakvinimodom
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
BRPI0821895A2 (pt) Composiçao farmacêutica, método de tratamento ou prevenção de uma doença, uma condição e sintomas das mesmas em animais de sangue quente, incluindo seres humanos, método de preparação da composição farmacêutica e método para diagnosticar uma doença, condição, síndrome.
BRPI0717741A2 (pt) Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
FR2864903B1 (fr) Appareil de traitement notamment par laser d'un cancer ou d'un etat precancereux
BRPI0607851A2 (pt) compostos e usos dos mesmos
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний